Interleukin enhancer-binding factor 3 (ILF3) antibody
-
- Target See all Interleukin enhancer-binding factor 3 (ILF3) Antibodies
- Interleukin enhancer-binding factor 3 (ILF3)
-
Reactivity
- Human, Mouse, Rat
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- Un-conjugated
-
Application
- Western Blotting (WB), Immunofluorescence (IF)
- Characteristics
- Polyclonal Antibody
- Purification
- Affinity purification
- Immunogen
- Recombinant fusion protein of human ILF3 (NP_036350.2).
- Isotype
- IgG
- Top Product
- Discover our top product ILF3 Primary Antibody
-
-
- Application Notes
- WB 1:500-1:2000 IF 1:50-1:200
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- -20 °C
- Storage Comment
- Store at -20°C. Avoid freeze / thaw cycles.
-
- Target
- Interleukin enhancer-binding factor 3 (ILF3)
- Alternative Name
- ILF3 (ILF3 Products)
- Background
- This gene encodes a double-stranded RNA (dsRNA) binding protein that complexes with other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate gene expression and stabilize mRNAs. This protein (NF90, ILF3) forms a heterodimer with a 45 kDa transcription factor (NF45, ILF2) required for T-cell expression of interleukin 2. This complex has been shown to affect the redistribution of nuclear mRNA to the cytoplasm. Knockdown of NF45 or NF90 protein retards cell growth, possibly by inhibition of mRNA stabilization. In contrast, an isoform (NF110) of this gene that is predominantly restricted to the nucleus has only minor effects on cell growth when its levels are reduced. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
- Molecular Weight
-
Observed_MW: 95 kDa/120 kDa
Calculated_MW: 74 kDa/75 kDa/76 kDa/82 kDa/95 kDa
- Gene ID
- 3609
- UniProt
- Q12906
- Pathways
- M Phase
-